-
news · 22 Jul 2026
In septic T cells, VDAC1 oligomers open a pore that leaks mtDNA and drives inflammation — and VBIT-12 shuts it down
A Shanghai team watched VDAC1 clump up, leak mtDNA, and trip the cGAS–STING alarm in immune cells — and calmed the whole thing down with the oligomerization blocker VBIT-12.
-
explainer · 12 Jul 2026
So what actually is VDAC1, and why do I care this much?
The on-ramp post: what the channel does, why 'the most abundant protein on the mitochondrial outer membrane' is a big deal, and how the same pore that keeps a cell alive can help kill it — with a spin-it-yourself 3D structure.
-
drug-watch · 8 Jul 2026
VBIT-4 & VBIT-12: the molecules trying to stop VDAC1 from ganging up
A running summary of the VBIT compounds that block VDAC1 oligomerization — where the idea came from, which disease models they've been tested in, and the honest caveats about how early it all still is.
-
news · 24 Jun 2026
x-tosis lands a $2.74M Michael J. Fox Foundation grant to push XTS001 — a brain-penetrant VDAC1-oligomerization blocker — toward Parkinson's
The most conflicted post on the site, flagged as such: x-tosis — the biotech I co-founded — just won a $2.74M grant from The Michael J. Fox Foundation to advance XTS001, an oral, brain-penetrant molecule that blocks VDAC1 oligomerization, into Parkinson's development.
